---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089932"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2024-08-02T23:59:59+00:00"
generated_at: "2026-05-31T13:22:07.135861+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BMS terminates AGEN1777 license; Agenus regains rights to TIGIT bispecific antibody

## Summary
- BMS voluntarily terminates AGEN1777 license agreement effective Jan 26, 2025, as part of strategic pipeline realignment.
- Agenus received $200M upfront plus $20M (Phase 1) and $25M (Phase 2) milestone payments from BMS since 2021.
- No early termination penalties; Agenus gets exclusive, royalty-free license to BMS know-how and patent rights for AGEN1777.
- BMS will assign all regulatory registrations and approvals for AGEN1777 back to Agenus.
- Agenus plans to explore further development or relicensing of AGEN1777, now with safety and clinical activity data.

## SEC filing metadata
- accession: 0000950170-24-089932
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2024-08-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000095017024089932/0000950170-24-089932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000095017024089932/agen-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089932
- JSON: https://secwatch.observer/filing/0000950170-24-089932.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.